The unit's first question is direct: is CRI's book shrinking R$ 8,4 million in May a sign of trouble? The short answer is no — at least not yet. What the Structured Monthly Report of May/2026 shows is a portfolio in defensive mode on the eve of the 13th issue: natural CRI depreciations that were not returned in the same month, cash rising 21% and net worth retreating 0,54%. Isolated, it is a common operational movement in paper funds with active management. The warning is only born if the contraction is repeated in the next reports — and that is exactly what this re-analysis puts as the 7th point of attention of the RECR11, with moderate severity.
The detail that makes the month interesting is the paradox: while the CRI book decreases, the dividend has gone the opposite way. The DPS of May/2026 was of R$ 1,118 — the largest in 13 monthsPaid today, 15/06/2026. Wallet shrinking and provent rising at the same time is no magical contradiction; there is explanation, and it is important to understand whether current income is sustainable or a punctual peak.
The May/2026 signal in detail
The Structured Monthly Report reported three movements that go together:
- PL retreated to R$ 2,338 bi, fall of 0,54% over April.
- The CRI portfolio shrunk ZQX0ZX mi, leaving from R$ 2,275 bi to R$ 2,267 bi.
- The liquidity requirement has grown 21%, reaching R$ 48,8 mi — the equivalent of 2,1% of the PL, above the usual level of the fund.
The technical reading is simple: in May, the CRI depreciations surpassed the new allocations. The RECR11 operates with intense active management — between 5 and 10 CRI drives per month — then a punctual mismatch between what comes in and what comes out of the book is expected. What weighs here are the hypotheses about Why? the cashier went up instead of the money being immediately relocated:
- Hypothesis A — pre-issue liquidity (most likely): the 13th issue was approved in april/2026 and the period of preference goes from 06/07 to 19/10/2026. It makes sense for the fund to hold the box and avoid compromising resources before having the new capital in hand, so as not to need to resell position later.
- Hypothesis B — Spread discipline (neutral): with Selic in 14,75%, the stall box yields a lot. If the fund manager does not see CRIs with proper spread at the moment, waiting is rational — the opportunity cost to stay liquid is low when the CDI is high.
- Hypothesis C — difficulty in origination (only bearish): if the CRI market is expensive or scarce and the contraction persists for two or three reports, then it becomes alert that management is not managing to rotate the book with the usual quality.
It is worth sizing the actual opportunity cost of this extra box. The R$ 8,4 mi that came out of the CRI book yielded, at the average purchase rate IPCA+ 8,58%, about R$ 60 thousand per month of real estate revenue. The fund cashier, applied in instruments linked to the CDI to 14,75%, generates in the house of R$ 530 thousand/month over the R$ 48,8 mi liquidity. That is, while Selic is high, getting liquid does not destroy income — on the contrary, it helps sustain income in the short term. It is not a crisis; it is a real data that helps to understand the month.
Dividing from R$ 1,118 — How Does It Stand Up?
The jump of the proceeds has concrete explanation and does not depend on the size of the CRI book. There are three sources:
- Cargo from the high box: with 2,1% of the PL applied in CDI to 14,75%, the net portion of the fund became relevant generating result in the month — precisely the effect of the opportunity cost described above.
- Monetary correction: 83% of the portfolio is indexed to IPCA+, with average rate of IPCA+ 8,58%. In months of firmer inflation, the correction of CRIs elevates the distributable result.
- Favorable market marking: The MtM of the RECR11 is volatile — fluctuated from +ZQX1ZX mi to −ZQX2ZX mi in monthly windows in the last 12 months. When it comes positive, it inflates the DPS; when it comes negative, it drops. Part of the May record dividend carries this component that no It's recurrent.
So the recent sequence — Mar/26 R$ 1,0335, Apr/26 R$ 1,0525, May/26 R$ 1,118 — shows clear acceleration, but needs to be handled with the mean 12 months of R$ 0,89 and the coefficient of variation of 19% next to it. The number of May is the roof of the belt, not the floor.
| Competence | DPS (R$) |
|---|---|
| Jun/25 | 1,0141 |
| jul/25 | 0,9510 |
| Aug/25 | 0,7815 |
| set/25 | 0,7422 |
| Oct/25 | 0,8037 |
| Nov/25 | 0,8194 |
| ten/25 | 0,8100 |
| Jan/26 | 0,8276 |
| Feb/26 | 0,7253 |
| Mar/26 | 1,0335 |
| Apr/26 | 1,0525 |
| May/26 | 1,118 ← maximum in 13 months |
Average 12m: R$ 0,89 · Minimum: R$ 0,72 · Maximum (24m): R$ 1,36 · CV: 19%. The honest reading is that RECR11 is a consistent payer, but with amplitude — don't count on R$ 1,118 every month.
13th issue: the quandary of the unit
The 13th issue was approved in April/2026: 4,6 million units to R$ 89, with a period of preference from 06/07 to 19/10/2026 and a proportion of 17,42% for those who are already unitholder. The decision to exercise or not to exercise shall consist of three paragraphs:
- Emission price R$ 89 against market quote R$ 80,50: Buying at issue costs more expensive than buying the unit at the market today. That’s the point that bothers you — the stock exchange discount makes the subscription less attractive in the screen price.
- R$ 89 against VPA R$ 88,42: the issue comes out practically in the asset value (minimum ~0,7%), which protects the relevant equity dilution unit holder. There is no entry below the PV, but there is also no predatory capture of who stays.
- Emission costs of 2,96% (~R$ 11 mi) borne by the fund: this is a legitimate point of attention (1st item). The expense comes out of the cashier and weighs in the short term, even if it dilutes over time if the new capital is well allocated.
In short: the issue is defensive for the equity (leave on the VP), but the cheaper screen price makes, for the most part, buying in the secondary market is more efficient than exercising R$ 89 — except for those who want to maintain exactly its proportion and avoid relative dilution.
Olympus Case — update
The Olympus case follows as the second point of attention of the thesis. The transaction became a payment via real estate, and the central asset — the Morumbi Plaza, evaluated in R$ 75,9 mi (~3,2% PL) — is outside the core of a paper bottom. The news of the report is that the period of exclusivity with the buyer expired without agreement (Relevant Fact 1192680), and the fund manager resumed negotiations with third parties.
This prolongs the undefinition: a property weighing on the balance sheet of a fund whose vocation is CRI is exactly the type of asset that the market prefers to see converted into a box. If the sale comes out profitably, there is room for extraordinary distribution; if it stops again, the fund carries an illiquid asset and out of office for longer. It's an overhang that doesn't change the thesis, but needs resolution.
Verdict and for whom it is
The set of grounds underpins the recommendation. The portfolio is extremely pulverized: 98 CRI operations (PL 90%), top-10 debtors in PL 21,7% only and 0,013 HHI — one of the smallest segment concentrations, spread across 14 states and 9 sectors. The REC record track reinforces: accumulated return of 158,3% against net CDI of 87,1% since Dec/2017, i.e. 82% above benchmark in 8 years.
Absolute note: 7,5/10 → KEEP
Comparative note: 7,3/10 → ACUMULAR (3rd of 12 in the paper bucket · multicategory · medium risk)
Bucket Peers: CCME11 (7,6 · 2º), XPCI11 (7,1 · 4º), WHGR11 (7,0 · 5º).
RECR11 to R$ 80,50 negotiates P/VP 0,91 (9% discount on R$ 88,42 VPA), with 13,27% DY a.a. and proven track record management. The May/2026 signal (CRI contracting) is monitoring, not output. For those seeking monthly income on high granular paper and tolerating the volatility of DPS via market marking, the discount on VP justifies accumulating — without ignoring the points of attention.
For whom it is: income investor who tolerates monthly variation of income (19% CV), understands that part of the DPS comes from non-recurrent marking and wants sprayed exposure to IPCA+ real estate credit. For those who are not: who seeks to divide fixed and predictable to the penny, or does not accept the risk of exposure to incorporation/crowding (62% of the portfolio), sensitive to high Selic.
Conclusion — What to Monitor
The RECR11 delivered in May a month of apparent contradiction that, dissected, makes sense: high cash yielding the 14,75%, IPCA correcting the book and favorable marking pushed the dividend to the top 13 months, while the fund held allocation waiting for the 13th issue. The thesis remains healthy and discounted. The new point — PL and CRI contracting — is of moderate severity precisely because a month does not tend.
What to follow in the following reports:
- CRI contraction persistence: if the book grows again with the input of the emission resources, Hypothesis A confirms itself and the theme comes off the radar. If it shrinks again, Hypothesis C gains strength.
- Box normalization: liquidity must return to the usual level after allocation of resources of the 13th issue. Persistently high box = idle capital.
- Outcome of Morumbi Plaza: sale with profit opens door to extraordinary proceeds; new locking prolongs the overhang.
- DPS support: see if the background holds the track R$ 1,00–1,12 or regresses to the historical average of R$ 0,89 when the market mark turns.
Favorable base scenario: With Focus projecting Selic falling from 14,75% to ~11% by the end of 2026, there is room for unit to rise 5–10% and P/VP to converge to VP — a trigger that values who accumulates in the current discount.
